SCHEMBL25890242

SCHEMBL25890242

CN1C(=O)C(C)(O)c2cccnc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 2/20 0.37
ADORA2A P29274 2/20 0.37
ADORA1 P30542 2/20 0.37
GAA P10253 2/20 0.36
LMNA P02545 2/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 4/20 0.35
KCNH2 Q12809 2/20 0.34
MYC P01106 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HCRTR1 O43613 1/20 0.34
MAPT P10636 1/20 0.34
PDK2 Q15119 2/20 0.34
CYP1A2 P05177 2/20 0.34
POLB P06746 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
RAD52 P43351 1/20 0.34
CYP2C19 P33261 1/20 0.33
FEN1 P39748 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3519201 0.83 LMNA (0.37) ADORA3ADORA2AADORA1GAALMNA
SCHEMBL25891411 0.80 ALDH1A1 (0.44) KMT2AMEN1ALDH1A1KCNH2KDM4E
SCHEMBL31389178 0.80 PDK2 (0.38) ADORA3ADORA2AADORA1GAALMNA
SCHEMBL31389184 0.78 SCN9A (0.42) GAAKMT2AMEN1MYCPDK2
SCHEMBL8687319 0.78 LMNA (0.35) ADORA3ADORA2AADORA1GAALMNA
SCHEMBL21993355 0.77 EGLN1 (0.41) KCNH2
SCHEMBL12990219 0.75 PDK2 (0.36) ADORA3ADORA2AADORA1LMNAKCNH2
SCHEMBL25890245 0.73 GAA (0.39) ADORA3ADORA2AADORA1GAALMNA
SCHEMBL23558587 0.72 EGLN1 (0.43) KCNH2
SCHEMBL25890238 0.72 RAD52 (0.55) GAALMNAKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234938-A1 NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2023-07-27 US disclosed
US-20230234938-A1 NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234938-A1 NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS PARP1, PARP2, PARP3 ADORA3 2390/4885ADORA2A 2100/4885ADORA1 3007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.